A Phase 2 of VIB7734 for the Treatment of Moderate to Severely Active SLE
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734
for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in
approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up
through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.